Peptides for Erectile Dysfunction: PT-141, BPC-157, and Vascular Peptides

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

PT-141 works centrally to increase sexual desire and arousal. BPC-157 improves vascular function and may address the vascular component of ED. For men with vascular ED, peptides that promote angiogenesis and endothelial function (BPC-157, GHK-Cu) complement the central effects of PT-141.

Understanding Erectile Dysfunction

Erectile dysfunction (ED) affects approximately 30 million men in the United States and is a complex condition with multiple contributing factors: vascular (reduced blood flow to penile tissue), neurological (impaired nerve signaling), hormonal (low testosterone, high estrogen), and psychological (anxiety, depression, relationship issues). Effective treatment requires addressing the relevant underlying causes rather than simply providing symptomatic relief.

PT-141: Central Mechanism

PT-141 (bremelanotide) is unique among ED treatments in that it works centrally — in the brain — rather than peripherally. By activating MC4R receptors in the hypothalamus and limbic system, PT-141 increases sexual desire and arousal, facilitating erection through the normal neurological pathways. This central mechanism means PT-141 is effective even in men with vascular ED who do not respond to PDE5 inhibitors, and it can be combined with PDE5 inhibitors for additive effects. Typical dosing: 1–2 mg subcutaneously 1–2 hours before sexual activity.

BPC-157 for Vascular ED

The vascular component of ED — impaired blood flow to the corpus cavernosum — is the most common underlying cause, particularly in older men and those with cardiovascular risk factors. BPC-157 promotes angiogenesis (new blood vessel formation) and improves endothelial function through its effects on the nitric oxide system. Animal studies have shown BPC-157 to improve erectile function in models of vascular ED. While human data is limited, the mechanistic rationale is compelling. Typical dosing: 250–500 mcg subcutaneously daily.

Testosterone Optimization

Low testosterone is a common and often overlooked contributor to ED. Testosterone is required for normal libido, nitric oxide synthase activity in penile tissue, and the psychological aspects of sexual function. Men with ED should have testosterone levels measured, and TRT should be considered if levels are suboptimal (below 400–500 ng/dL).

Combining Approaches

The most effective approach to ED combines: hormonal optimization (TRT if indicated), central stimulation (PT-141), vascular support (BPC-157, lifestyle modifications), and psychological support if needed. This multi-modal approach addresses the multiple contributing factors simultaneously and produces better outcomes than any single intervention.